Actio Biosciences was founded on an understanding that developing new drugs for rare diseases can inform novel treatment approaches for common diseases.
Actio has built an integrated drug discovery engine that leverages deep expertise in human genetics and bioinformatics to identify shared biology between rare and common diseases. Through the development of precision medicines for homogenous rare patient populations, Actio builds on a foundation of data to rationally target large, heterogeneous patient populations.
Actio is developing a pipeline of new medicines with the goal to enhance the probability of clinical success and deliver better medicines for all patients.